



#### UNITED STATES PATENTIAND TRADEMARK OFFICE

Correctissioner for Patients, Box PCT United States Patient and Trademark Ciffice Washington, D.C., 2023

 U.S. APPLICATION NUMBER NO.
 FIRST NAMED APPLICANT
 ATTY. DOCKET NO.

 09/807,576
 Timothy P. Clackson
 384A PCT/US

 INTERNATIONAL APPLICATION NO.
 PCT/US99/24328

 LA. FILING DATE
 PRIORITY DATE

 David L Berstein
 10/19/1999
 10/19/1998

David L Berstein Ariad Pharmaceuticals Inc 26 Landsdowne Street Cambridge, MA 02139-4234

CONFIRMATION NO. 9109
371 FORMALITIES LETTER
CC0000000007140913\*

Date Mailed: 12/05/2001

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Claims
- · Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Request for Immediate Examination
- Small Entity Statement
- Small Entity Statement

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by



## 37 CFR 1.821(e).

- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

## ANITA D JOHNSON

Telephone: (703) 305-3661

#### PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
09/807,576	PCT/US99/24328	384A PCT/US